Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
Open accessAbstract
Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Preliminary studies of aripiprazole in FXS have found evidence for an improvement in clinical symptoms and irritability.
“Preliminary studies of aripiprazole in FXS have also found evidence for an improvement in clinical symptoms and irritability [732,733].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [732]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · see citing works
Self-citation(1985) · PubMed · Cited by 1,427 · see citing works
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S. M., Arrington, E. G., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 971 · see citing works
Burris, K. D., Molski, T. F. P., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 924 · see citing works
Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007
Kogan, M. D., Blumberg, S. J., Schieve, L. A., Boyle, C. A., Perrin, J. M., Ghandour, R. M., Singh, G. K., Strickland, B. B., Trevathan, E., & van Dyck, P. C. (2009) · Pediatrics · doi:10.1542/peds.2009-1522 · Cited by 892 · see citing works
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715 · see citing works
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · see citing works
Advances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596 · see citing works
Shea, S. E., Turgay, A., Carroll, A. M., Schulz, M., Orlik, H., Smith, I. M., & Dunbar, F. (2004) · PEDIATRICS · doi:10.1542/peds.2003-0264-f · Cited by 567 · see citing works
Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b76658 · Cited by 563 · see citing works
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512 · see citing works
Co‐occurring conditions associated with FMR1 gene variations: Findings from a national parent survey
Bailey, D. B., Raspa, M., Olmsted, M. G., & Holiday, D. B. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32439 · Cited by 445 · see citing works
Neurochemistry in the pathophysiology of autism.
McDougle, C. J., Erickson, C. A., Stigler, K. A., & Posey, D. J. (2005) · PubMed · Cited by 408 · see citing works
Self-citationAutistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP
Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B., Roberts, J., & Mirrett, P. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31286 · Cited by 359 · see citing works
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276 · see citing works
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
on behalf of the Aripiprazole Study Group, Casey, D. E., Carson, W. H., Saha, A. R., Liebeskind, A., Ali, M. W., Jody, D. N., & Ingenito, G. G. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1344-3 · Cited by 250 · see citing works
Hessl, D. R., Tassone, F., Loesch, D. Z., Berry‐Kravis, E., Leehey, M. A., Gane, L. W., Barbato, I. T., Rice, C. D., Gould, E. L., Hall, D. A., et al. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30241 · Cited by 233 · see citing works
Bailey, D. B., Hatton, D. D., Skinner, M. L., & Mesibov, G. B. (2001) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1010747131386 · Cited by 207 · see citing works
Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson, G. M., Scahill, L. D., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., Arnold, L. E., Martin, A., Katsovich, L., Posey, D. J., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.032 · Cited by 176 · see citing works
Self-citationPsychopharmacology in fragile X syndrome—Present and future
Berry‐Kravis, E., & Potanos, K. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20007 · Cited by 151 · see citing works
Amygdala dysfunction in men with the fragile X premutation
Hessl, D. R., Rivera, S. M., Koldewyn, K., Cordeiro, L., Adams, J., Tassone, F., Hagerman, P. J., & Hagerman, R. J. (2006) · Brain · doi:10.1093/brain/awl338 · Cited by 128 · see citing works
Neurobehavioral phenotype in carriers of the fragile X premutation
Johnston, C. K., D, S. E. M., Dyer-Friedman, J., Hessl, D. R., Glaser, B., Blasey, C. M., Taylor, A. K., & Reiss, A. L. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1561 · Cited by 119 · see citing works
Aripiprazole for Maladaptive Behavior in Pervasive Developmental Disorders
Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.455 · Cited by 108 · see citing works
Self-citationStigler, K. A., Diener, J. T., Kohn, A. E., Li, L., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.093 · Cited by 98 · see citing works
Self-citationValicenti-McDermott, M., & Demb, H. B. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.549 · Cited by 81 · see citing works
Open-Label Memantine in Fragile X Syndrome
Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-009-0807-3 · Cited by 61 · see citing works
Self-citationAripiprazole Monotherapy in Children and Young Adolescents with Pervasive Developmental Disorders
Masi, G., Cosenza, A., Millepiedi, S., Muratori, F., Pari, C., & Salvadori, F. (2009) · CNS Drugs · doi:10.2165/00023210-200923060-00005 · Cited by 58 · see citing works
Inoue, A., & Nakata, Y. (2001) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.86.376 · Cited by 31 · see citing works
Medication use in fragile X syndrome
Amaria, R. N., Billeisen, L. L., & Hagerman, R. J. (2001) · Cited by 27 · see citing works
Pharmacologic Treatment of Autism and Related Disorders
Erickson, C. A., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2007) · Pediatric Annals · doi:10.3928/0090-4481-20070901-09 · Cited by 23 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [28]Aman MG Kasper W Manos G Aripiprazole in the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years old): Line-item analysis of the Aberrant Behavior Checklist Irritability Subscale 56th American Academy of Child & Adolescent Psychiatry Meeting Honolulu, HI 2009 20973712
Cited by
Sorted by citations
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838 · see citing works
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336 · see citing works
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S. E., Srivorakiat, L., Wink, L. K., Pedapati, E. V., & Erickson, C. A. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 279 · see citing works
Self-citationAutism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment
Kaufmann, W. E., Kidd, S. A., Andrews, H. F., Budimirovic, D. B., Esler, A., Haas-Givler, B., Stackhouse, T., Riley, C., Peacock, G., Sherman, S. L., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2016-1159f · Cited by 268 · see citing works
Aripiprazole for autism spectrum disorders (ASD)
Hirsch, L., & Pringsheim, T. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009043.pub3 · Cited by 203 · see citing works
Fragile X Syndrome and Targeted Treatment Trials
Hagerman, R. J., Lauterborn, J. C., Au, J., & Berry‐Kravis, E. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_17 · Cited by 104 · see citing works
Targeted treatments for fragile X syndrome
Berry‐Kravis, E., Knox, A. T., & Hervey, C. M. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9074-7 · Cited by 103 · see citing works
Politte, L. C., & McDougle, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3068-y · Cited by 94 · see citing works
Self-citationTranfaglia, M. R. (2011) · Developmental Neuroscience · doi:10.1159/000329421 · Cited by 89 · see citing works
Potential therapeutic interventions for fragile X syndrome
Levenga, J., de Vrij, F. M. S., Oostra, B. A., & Willemsen, R. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.08.005 · Cited by 87 · see citing works
Aripiprazole for autism spectrum disorders (ASD)
Ching, H., & Pringsheim, T. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009043.pub2 · Cited by 83 · see citing works
Sharma, R., Rahi, S., & Mehan, S. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.10.019 · Cited by 81 · see citing works
A prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69 · see citing works
Self-citationUnstable Mutations in the FMR1 Gene and the Phenotypes
Loesch, D. Z., & Hagerman, R. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5434-2_6 · Cited by 68 · see citing works
Zohny, S. M., Habib, M. Z., Mohamad, M. I., Elayat, W. M., Elhossiny, R. M., El-Salam, M. F. A., Hassan, G. A. M., & Aboul‐Fotouh, S. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01360-w · Cited by 59 · see citing works
The FRAXopathies: Definition, overview, and update
Pirozzi, F., Tabolacci, E., & Neri, G. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34113 · Cited by 46 · see citing works
Aripiprazole for the treatment of irritability associated with autism
Farmer, C., & Aman, M. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.557661 · Cited by 46 · see citing works
Gipson, T., & Johnston, M. V. (2012) · Neural Plasticity · doi:10.1155/2012/486402 · Cited by 44 · see citing works
Early Identification of Fragile X Syndrome through Expanded Newborn Screening
Okoniewski, K. C., Wheeler, A., Lee, S., Boyea, B. L., Raspa, M., Taylor, J. L., & Bailey, D. B. (2019) · Brain Sciences · doi:10.3390/brainsci9010004 · Cited by 36 · see citing works
Eckert, E. M., Dominick, K. C., Pedapati, E. V., Wink, L. K., Shaffer, R. C., Andrews, H., Choo, T.-H. J., Chen, C., Kaufmann, W. E., Tartaglia, N. R., et al. (2019) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04173-z · Cited by 36 · see citing works
Self-citationA Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination
Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 36 · see citing works
The promising trajectory of autism therapeutics discovery
Silverman, J. L., & Crawley, J. N. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.007 · Cited by 34 · see citing works
Review of the pharmacotherapy of irritability of autism.
Elbe, D., & Lalani, Z. (2012) · PubMed Central · Cited by 34 · see citing works
Ishima, T., Iyo, M., & Hashimoto, K. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.97 · Cited by 34 · see citing works
Rafaniello, C., Pozzi, M., Pisano, S., Ferrajolo, C., Bertella, S., Sportiello, L., Carnovale, C., Sullo, M. G., Cattaneo, D., Gentili, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1229301 · Cited by 33 · see citing works
Pharmacotherapy for Fragile X Syndrome: Progress to Date
Davenport, M. H., Schaefer, T. L., Friedmann, K., Fitzpatrick, S. E., & Erickson, C. A. (2016) · Drugs · doi:10.1007/s40265-016-0542-y · Cited by 31 · see citing works
Self-citationHannan, A. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5434-2_1 · Cited by 32 · see citing works
Improvement of ketamine-induced social withdrawal in rats
Hołuj, M., Popik, P., & Nikiforuk, A. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000132 · Cited by 27 · see citing works
Kumar, M., Mehan, S., Kumar, A., Sharma, T., Khan, Z., Tiwari, A., Gupta, G. D., & Narula, A. S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149251 · Cited by 25 · see citing works
Sudhahar, S., Özer, B., Chang, J., Chadwick, W., O’Donovan, D., Campbell, A., Tulip, E., Thompson, N. T., & Roberts, I. (2024) · Nature Communications · doi:10.1038/s41467-024-50024-6 · Cited by 20 · see citing works
Tiwari, A., Rahi, S., & Mehan, S. (2020) · Current Drug Targets · doi:10.2174/1389450121666201020155010 · Cited by 19 · see citing works
Shaffer, R. C., Reisinger, D. L., Schmitt, L., Lamy, M., Dominick, K. C., Smith, E. G., Coffman, M. C., & Esbensen, A. J. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.06.020 · Cited by 20 · see citing works
A pathway profile-based method for drug repositioning
Ye, H., Yang, L., Cao, Z., Tang, K., & Li, Y. (2012) · Chinese Science Bulletin · doi:10.1007/s11434-012-4982-9 · Cited by 19 · see citing works
Lurasidone for the treatment of irritability and anger in autism spectrum disorders
McClellan, L., Dominick, K. C., Pedapati, E. V., Wink, L. K., & Erickson, C. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1353600 · Cited by 18 · see citing works
Self-citationBarcellos, H. H. D. A., Pompermaier, A., Soares, S. M., Maffi, V. C., Fernandes, M., Koakoski, G., Kirsten, K., Baldisserotto, B., & Barcellos, L. J. G. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172841 · Cited by 17 · see citing works
The need for a comprehensive molecular characterization of autism spectrum disorders
Broek, J. A. C., Brombacher, E., Stelzhammer, V., Guest, P. C., Rahmoune, H., & Bahn, S. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571300117x · Cited by 16 · see citing works
Aripiprazole for treating irritability in children & adolescents with autism: A systematic review
Ghanizadeh, A. J., Tordjman, S., & Jaafari, N. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.166584 · Cited by 16 · see citing works
New Therapeutic Options for Fragile X Syndrome
Jalnapurkar, I. R., Cochran, D., & Frazier, J. A. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0551-8 · Cited by 15 · see citing works
Fragile X Syndrome: A Psychiatric Perspective
Tranfaglia, M. R. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_16 · Cited by 14 · see citing works
Khan, F., Rahman, M. S., Akhter, S., Momen, A., & Raihan, S. G. (2021) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v32i1.51089 · Cited by 13 · see citing works
Hall, S. S., Hammond, J. L., Hirt, M., & Reiss, A. L. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01560.x · Cited by 12 · see citing works
A fourth case of Feingold syndrome type 2: psychiatric presentation and management
Ganjavi, H., Siu, V. M., Speevak, M. D., & MacDonald, P. A. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-207501 · Cited by 12 · see citing works
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
Hagerman, R. J., & Hagerman, P. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-090147 · Cited by 12 · see citing works
Current status of biological treatment options in Autism Spectrum Disorder
Eapen, V., Nicholls, L. E., Spagnol, V., & Mathew, N. E. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.07.025 · Cited by 11 · see citing works
Altered brain serotonin 5-HT1A receptor expression and function in juvenile Fmr1 knockout mice
Saraf, T. S., Chen, Y., Tyagi, R., & Canal, C. E. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109774 · Cited by 9 · see citing works
Pugin, A., Faùndes, V., María, L. S., Curotto, B., Aliaga, S., Salas, I., Soto, P., Bravo, P. E., Pena, M., & Alliende, M. A. (2014) · Neurología · doi:10.1016/j.nrl.2014.10.009 · Cited by 9 · see citing works
Studying child development in genetic models of ASD
Garg, S., & Green, J. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.009 · Cited by 8 · see citing works
Sex Differences in Dopamine Receptor Signaling in Fmr1 Knockout Mice: A Pilot Study
Jiang, A., Wang, L., Lu, J., Freeman, A., Campbell, C., Su, P., Wong, A. H. C., & Liu, F. (2021) · Brain Sciences · doi:10.3390/brainsci11111398 · Cited by 7 · see citing works
Sharma, R., Tiwari, A., Rahi, S., & Mehan, S. (2020) · Current Psychopharmacologye · doi:10.2174/1389203721999200820165117 · Cited by 6 · see citing works
Mystery of Expansion: DNA Metabolism and Unstable Repeats
Grishchenko, I. V., Purvinsh, Y. V., & Yudkin, D. V. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41283-8_7 · Cited by 4 · see citing works
Clinical, molecular, and pharmacological aspects of FMR1 -related disorders
Pugin, A., Faùndes, V., María, L. S., Curotto, B., Aliaga, S., Salas, I., Soto, P., Bravo, P. E., Pena, M., & Alliende, M. A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.10.018 · Cited by 4 · see citing works
Verhoeven, W. M. A., & Egger, J. I. M. (2014) · Journal of Intellectual Disability - Diagnosis and Treatment · doi:10.6000/2292-2598.2014.02.02.1 · Cited by 3 · see citing works
Reflections on Clinical Trials in Fragile X Syndrome
Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2 · see citing works
Emerging Research towards the Understanding and Treatment of Autism
Wang, P. P., Hammond, R., Postma, F. R., & Healy, A. M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00384 · Cited by 1 · see citing works
Delayed onset of striatal projection neuron hyperexcitability in Fmr1−/y mice
Nelson, L., Janeček, M., Matarazzo, M., Shih, Y.-C., & Peixoto, R. T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1667476 · Cited by 1 · see citing works
Aripiprazol: farmacología, eficacia clínica, seguridad y tolerabilidad en el adulto.
Belloso, F. J. D., & Loza, A. S. (2011) · Psiquiatria.com · Cited by 1 · see citing works
Sleep and Sleep Problems in Children with Neurologic Disorders
Grigg-Damberger, M. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1703-7.10040-4 · Cited by 1 · see citing works
唐, 凯., 叶, 浩., 李, 亦., 杨, 琳., & 曹, 志. (2012) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb2012-57-7-534 · Cited by 1 · see citing works
(2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834585ec · Cited by 1 · see citing works
Contratación por internet: la revolución jurídica del siglo XXI
Belupu, H. Ñ. (2002) · Advocatus · doi:10.26439/advocatus2002.n006.2348
(2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834dda34
Late onset of striatal projection neuron hyperexcitability in Fmr1 -/y micePreprint
Nelson, L., Janeček, M., Matarazzo, M., Shih, Y.-C., & Peixoto, R. T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.21.660889
Utilization of psychotropic medications in individuals with autism spectrum disorder
Jaimes-Buitron, P. A., Neely, L. C., Svoboda, M., Gemeinhardt, G. L., & Vivas-Valencia, C. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07714-2
Han, J. H., Kim, Y. R., Lee, Y., Park, Y., Kim, D., Bong, G., & Yoo, H. J. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00838
- Authors
- Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J.
- Affiliations
- Indiana University School of Medicine (US)
- Riley Hospital for Children (US)
- Corresponding author
- Erickson, Craig A.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 7
- Issue
- 3
- Pages
- 258-263
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC2911359
- OpenAlex
- W1987566583
- Cited by
- 65
- References
- 32
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 1 · 2017: 7 · 2016: 5 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 11
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH077600)
- National Center for Research Resources (K12 UL1 RR025761, UL1RR025761)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- aripiprazole, autism spectrum disorder, fragile X syndrome, irritability, atypical antipsychotics, self-harm, aggression, tantrums, youth
- MeSH terms
- Aripiprazole, Child, Child Development Disorders, Pervasive, Fragile X Syndrome, Humans, Piperazines, Antipsychotic Agents, Quinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
